GLP vs. GLP-1: What’s the Difference and Why It Matters
Understand the difference between GLP and GLP-1, and how GLP-1 treatment plans may be considered by licensed providers as part of your personalized wellness care.
Comparing GLP-1 vs SGLT2 for metabolic health? Learn how licensed healthcare providers may recommend treatments based on your unique health goals.
Disclaimer: This content is for educational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider. Eden connects individuals with licensed providers who offer personalized treatment advice and plans.
If you’re researching treatment options to support metabolic health, including blood sugar regulation and weight-related concerns, you may have come across two medication types: GLP-1 receptor agonists and SGLT2 inhibitors. These are both FDA-approved for managing type 2 diabetes and may be discussed as part of an individualized treatment plan.
This guide explains the differences between GLP-1 and SGLT2 medications, how they work, and how a licensed medical provider may help you understand which option fits your health needs, if appropriate based on an individual health evaluation.
GLP-1 receptor agonists and SGLT2 inhibitors are both used to help manage type 2 diabetes. They are often considered as part of a broader metabolic care approach, depending on a patient's health profile. While these medications are effective in supporting blood sugar regulation, their methods of action and additional considerations vary significantly.
GLP-1 receptor agonists, such as semaglutide or liraglutide, mimic a naturally occurring hormone called glucagon-like peptide-1. This hormone plays a role in:
These medications are typically administered via injection or oral tablets, depending on the formulation.
{{primary-cta}}
SGLT2 inhibitors, such as Jardiance® or Farxiga®, work by targeting a protein in the kidneys that normally reabsorbs glucose. By inhibiting this protein, more glucose is removed from the body through urine. These medications are available in oral tablet form.
Only a licensed healthcare provider can determine whether a GLP-1 or SGLT2 medication may be appropriate. Your provider will evaluate:
For individuals seeking support with metabolic health, GLP-1 medications may be considered, especially when lifestyle changes alone haven’t delivered desired outcomes. Some GLP-1 medications are FDA-approved for long-term weight management.
In certain clinical scenarios, licensed providers may consider using both a GLP-1 and an SGLT2 inhibitor for patients with complex metabolic needs. Published studies suggest that combining both medications may provide added support for blood sugar management and risk reduction in eligible patients.
However, combination therapy decisions must be guided by a licensed provider and are based on a thorough review of your medical history, current medications, and lab results.
{{primary-cta}}
Eden is a digital health platform that connects individuals with licensed healthcare providers who may prescribe GLP-1 medications when clinically appropriate.
Our process is private, personalized, and designed to help you make informed decisions about your care. If you're interested in exploring GLP-1 treatment options, a licensed provider on the Eden platform can review your health history and determine if a treatment program is right for you.
Please note: Eden does not currently facilitate access to SGLT2 inhibitors.
GLP-1 and SGLT2 medications are both FDA-approved options for managing type 2 diabetes. GLP-1 medications work by mimicking natural hormones involved in insulin and appetite regulation, while SGLT2 inhibitors help lower blood sugar by promoting glucose loss through the kidneys.
Some GLP-1 medications are also approved for weight management in eligible patients, and licensed providers on the Eden platform may prescribe them as part of a customized care plan.
If you’re considering medical options to support your metabolic health, speaking with a licensed provider can help you understand your options.
Disclaimer: Eden is not a medical provider or a pharmacy. Eden connects individuals with independent licensed healthcare providers who independently evaluate each patient to determine whether a prescription treatment program is appropriate. All prescriptions are written at the sole discretion of the licensed provider. Medications are filled by independent, state-licensed pharmacies. Eden does not manufacture, own, or dispense any medications. No health claims are made unless supported by multiple peer-reviewed studies. Please consult a licensed healthcare provider before making any medical decisions.
Disclaimer: The FDA does not approve compounded medications for safety, quality, or manufacturing. Prescriptions and a medical evaluation are required for certain products. The information provided on this blog is for general informational purposes only. It is not intended as a substitute for professional advice from a qualified healthcare professional and should not be relied upon as personal health advice. The information contained in this blog is not meant to diagnose, treat, cure, or prevent any disease. Readers are advised to consult with a qualified healthcare professional for any medical concerns, including side effects. Use of this blog's information is at your own risk. The blog owner is not responsible for any adverse effects or consequences resulting from the use of any suggestions or information provided in this blog.
Brown, E., Heerspink, H. J. L., Cuthbertson, D. J., & Wilding, J. P. H. (2021). SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications. The Lancet, 398(10296), 262–276. https://doi.org/10.1016/s0140-6736(21)00536-5